tiprankstipranks
Trending News
More News >

Clover Biopharmaceuticals Ends Distribution Agreement with Adimmune

Story Highlights
Clover Biopharmaceuticals Ends Distribution Agreement with Adimmune

Don’t Miss TipRanks’ Half-Year Sale

Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an update.

Clover Biopharmaceuticals Ltd. announced the termination of its exclusive agreement with Adimmune Corporation to distribute AdimFlu-S (QIS) in mainland China, effective June 30, 2025, due to material changes in market conditions. The company believes this termination will not adversely impact its operations and remains focused on advancing its RSV vaccine candidate SCB-1019, which is part of its strategic objectives.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals Ltd. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on developing vaccines, including its proprietary RSV vaccine candidate SCB-1019, aimed at addressing respiratory health needs.

Average Trading Volume: 1,448,367

Technical Sentiment Signal: Hold

Current Market Cap: HK$337.2M

Learn more about 2197 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1